Spire Healthcare Group (LON:SPI) PT Raised to GBX 300

Spire Healthcare Group (LON:SPI) had its target price upped by stock analysts at Berenberg Bank from GBX 286 ($3.56) to GBX 300 ($3.73) in a research note issued on Wednesday, Digital Look reports. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s price objective would suggest a potential upside of 21.70% from the company’s previous close.

Separately, JPMorgan Chase & Co. reiterated an “overweight” rating and set a GBX 295 ($3.67) price objective on shares of Spire Healthcare Group in a research note on Monday, February 26th.

Spire Healthcare Group Price Performance

Shares of LON:SPI opened at GBX 246.50 ($3.07) on Wednesday. Spire Healthcare Group has a fifty-two week low of GBX 204 ($2.54) and a fifty-two week high of GBX 321.71 ($4.00). The firm has a market cap of £996.18 million, a price-to-earnings ratio of 3,521.43, a price-to-earnings-growth ratio of 1.06 and a beta of 0.99. The company has a debt-to-equity ratio of 170.37, a quick ratio of 0.74 and a current ratio of 0.69. The business has a 50-day simple moving average of GBX 237.41 and a two-hundred day simple moving average of GBX 228.84.

Spire Healthcare Group Company Profile

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.